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Giorgio Scagliotti, MD, PhDAbstract: Platinum-based therapy remains the standard of care
for the first-line treatment of patients with advanced non-small cell
lung cancer (NSCLC). When combined with a third-generation
agent, platinum-based doublets improve survival compared with
the third-generation agent given alone. Controversy remains, how-
ever, regarding the relative risks and benefits of the third-generation
agents. Four large phase III trials have addressed this question, with
only one trial finding a survival benefit in one of the treatment arms.
TAX 326 compared docetaxel-based therapy with vinorelbine/
cisplatin, and found that survival, response, and quality of life
outcomes all favoured the docetaxel/cisplatin regimen. Consistent
benefits have been reported with this regimen in other studies. The
non-platinum-based docetaxel/gemcitabine combination is an
alternative for patients who are not suitable candidates for
platinum-based therapy. Other results have shown that single-agent
docetaxel is an appropriate option for elderly patients and those
with poor performance status. Overall, the wealth of data with
docetaxel in advanced NSCLC suggests that it plays an important
role in first-line treatment and, as a single agent, can be considered
a reasonable approach in elderly and frail patients.
Key Words: Non-small cell lung cancer, Advanced disease,
First-line, Docetaxel, Vinorelbine, Cisplatin.
(J Thorac Oncol. 2007; suppl. 2: S86–S91)INTRODUCTION
Chemotherapy improves survival for patients withadvanced non-small cell lung cancer (NSCLC), and
first-line treatment for patients with a good performance
status (PS) generally includes two chemotherapy agents with
different mechanisms of action and safety profiles.
Platinum-based therapy has been the standard for over
two decades, and when combined with a third-generation
agent such as a taxane, gemcitabine, or vinorelbine, there
appears to be a small but significant survival advantage
associated with the use of cisplatin over carboplatin
(Figure 1).1 This finding has been confirmed in a second© Adis Data Information BV. Una
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Journal of Thoracimeta-analysis, which was conducted with individual patient
data, and found an 11% reduction in the relative risk of death
with cisplatin in this setting ( p¼ 0.026).2 Treatment
guidelines now recognize that non-platinum-based doublets
can also play a role in the management of advanced NSCLC
for selected patients, as can single-agent therapy for elderly
patients or those with poor PS.3 The question remains,
however, as to whether there is a preferred third-generation
agent to use for the treatment of advanced NSCLC.
Accumulating evidence suggests that docetaxel is an
effective agent with an acceptable safety profile in the
advanced NSCLC population.
FIRST-LINE THERAPY
The question of which third-generation agent to
combine with platinum therapy has been addressed
in a number of randomized phase III clinical trials. Most
have found no significant differences among the
combinations in terms of efficacy (Table 1),4–7 whereas
toxicity profiles, the cost of treatment and quality of life
endpoints sometimes varied significantly from one regimen
to the others. In the TAX 326 randomized trial comparing
standard vinorelbine/cisplatin (VC) with docetaxel/cisplatin
(DC) and docetaxel/carboplatin (DCb), treatment with DC
produced an 11% increase in survival compared with VC
(hazard ratio [HR] 1.183; p¼ 0.044).7 The median survival
time (MST) of 11.3 months with DC is one of the longest
demonstrated in recent clinical trials (Table 1); unlike the
other three trials, however, a higher proportion of patients
with stage III disease were included. In addition, the
response rate was significantly higher in the DC arm
(32 versus 25%, respectively; p¼ 0.029). The 2-year
survival rate was 50% higher with DC (21 versus 14%,
respectively; p¼NS). Grade 3/4 adverse events were more
common in the VC arm (48%) than in either of the docetaxel
arms (DC 41%; DCb 40%). There were no differences
among treatment groups in the incidence of grade 3/4
neutropenia, thrombocytopenia, or infection. Febrile
neutropenia occurred in fewer than 5% of patients in each
group. Grade 3/4 anaemia was more common with VC
(24 versus 7% with DC and 11% with DCb; p< 0.01 for
each comparison). For non-haematological toxicities, grade
3/4 nausea and vomiting were more common with VC than
with DC or DCb ( p< 0.01 for each comparison). In that
study, quality of life (QoL) was prospectively evaluated with
the validated Lung Cancer Symptom Scale, and both
docetaxel regimens were associated with improvements inuthorized reproduction of this article is prohibited.
c Oncology * Volume 2, Number 6, Supplement 2, June 2007
Rosell et al (2002)
Schiller et al (2002)
Zatloukal et al (2002)
Fossella et al (2002)
Combined
Mazzanti et al (2003)
0.75 1.0 1.25 1.5
HR = 1.106 ; p = 0.039
HR
Favours carboplatin-based chemotherapy Favours carboplatin-based chemotherapy
FIGURE 1. Overall Survival: Cisplatin Plus New Agent
Versus Carboplatin Plus New Agent.1
HR, hazard ratio.
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FIGURE 2. Changes from Baseline in Lung Cancer
Symptom Scale Item ‘QoL Today’ in TAX 326.8
DC, docetaxel/cisplatin; DCb, docetaxel/carboplatin; VC, vinorelbine/
cisplatin.
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Chemotherapy for Advanced NSCLCQoL, whereas QoL worsened for those receiving VC
(Figure 2).8 Patients treated with DC experienced greater
pain relief than did those receiving VC ( p¼ 0.033), less
deterioration in the PS score ( p< 0.001), and less weight
loss ( p< 0.001). Overall, the results of the study show that
the docetaxel/cisplatin combination improves survival,
QoL, and symptom control with an acceptable safety profile
in patients with advanced NSCLC.
The survival findings from the TAX 326 study are
consistent with the results of other trials of first-line docetaxel/
cisplatin (Figure 3).9,10 Douillard and colleagues9 conducted a
randomized phase II trial of DC compared with VC as first-
line therapy in 233 patients with stage IV NSCLC. After six
cycles, patients received maintenance therapy with single-
agent docetaxel or vinorelbine, respectively, and at
progression, patients were crossed over to the other agent
as monotherapy. Outcomes were similar for the two treatment
arms. The median survival time was 8.3 months with DC and
9.0 months with VC ( p¼ 0.38). The 1- and 2-year survival
rates were 37 and 17% with DC, and 36 and 10% with VC. In a
larger phase III trial, the combination of docetaxel/cisplatin
significantly improved MST compared with vindesine/
cisplatin in 302 patients with stage IV NSCLC (MST 11.3Copyright © Adis Data Information BV. Una
TABLE 1. Comparison of Major Randomized Trials in Adva
Regimen N Stage IV, %
SWOG 95094 VC 202 89
Pac225/Cb 206 88
ECOG 15945 Pac135/Cis 288 89
GC 288 86
DC 289 86
Pac225/Cb 290 86
ILCP6 VC 201 81
GC 205 81
Pac225/Cb 201 82
TAX 3267 VC 404 67
DC 408 67
DCb 406 67
DC, docetaxel/cisplatin; DCb, docetaxel/carboplatin; GC, gemcitabine/cisplatin;
Pac135/Cis, paclitaxel 135 mg/m2 plus cisplatin; Pac225/Cb, paclitaxel 225 mg/m
p¼ 0.029 for DC versus VC.
y p¼ 0.044 for DC versus VC.
 2007 International Association for the Study of Lung Cancermonths versus 9.6 months, respectively; p¼ 0.014).10 The
1- and 2-year survival rates were 48 and 24% with DC and 41
and 12% with vindesine/cisplatin.
For patients intolerant of or with a contraindication to
platinum-based therapy, a combination of docetaxel/
gemcitabine (DG) is a reasonable alternative for first-line
therapy. Two phase III clinical trials have demonstrated that
this combination is at least as effective as the VC
combination but better tolerated.11,12 In the trial by Pujol
et al.12 (N¼ 311), MST was higher with DG than with VS
(11.1 versus 9.6 months), but this difference was not
statistically significant. The DG regimen was generally
better tolerated than the VC regimen. For example, neither
group received prophylactic granulocyte colony-stimulating
factor, but the rates of both grade 3/4 neutropenia and febrile
neutropenia were significantly lower with DG (52 and 8.4%,
respectively) than with VC (83 and 22%, respectively;
p< 0.001 for each comparison). Grade 3/4 anaemia was also
more common with VC (21 versus 6%; p< 0.001). In the
trial by Georgoulias et al.11 (N¼ 413), there were no
differences in survival outcomes (MST 9.0 months for DGuthorized reproduction of this article is prohibited.
nced Non-small Cell Lung Cancer.
ORR, % MST, months 1-year OS, %
28 8.1 36
25 8.6 38
21 7.8 31
22 8.1 36
17 7.4 31
17 8.1 34
30 9.5 37
30 9.8 37
32 9.9 43
25 10.1 41
32 11.3y 46
24 9.4 38
MST, median survival time; ORR, overall response rate; OS, overall survival;
2 plus carboplatin; VC, vinorelbine/cisplatin.
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FIGURE 3. Survival at 2 Years in Randomized Trials of
First-line Docetaxel/Cisplatin for Advanced Non-small Cell
Lung Cancer.7,9,10
Cis, cisplatin; Doc, docetaxel; HR, hazard ratio; Vin, vinorelbine.
Scagliotti Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007and 9.7 months for VC) or overall response rates (30 and
39%, respectively). Again, the DG regimen was generally
better tolerated than VC. Both groups received prophylactic
granulocyte colony-stimulating factor, but the incidence of
grade 3/4 neutropenia was significantly reduced with DG
(16 versus 37%, respectively; p¼ 0.0001), as was the
incidence of febrile neutropenia (6 versus 11%; p¼ 0.009).
Grade 3/4 nausea and vomiting was also more common with
VC (15 versus 1%; p¼ 0.003). In addition, QoL scores on
the Lung Cancer Symptom Scale were improved from
baseline in the DG group for haemoptysis and pain; no
changes in symptom scores were seen in the VC group from
baseline to end of therapy.
Meta-Analysis
When summarizing the results of all of the published
comparative clinical trials of docetaxel-based compared
with vinca alkaloid-based therapy, it becomes clear that the
point estimates for overall survival in each trial tend to
favour docetaxel. Meta-analysis is a useful tool to define
more precisely the magnitude of treatment benefit
associated with therapy. Douillard and colleagues13Copyright © Adis Data Information BV. Una
TABLE 2. Published Trials of Docetaxel Versus Vinca Alkalo
Trial Population Docetaxel Regime
TAX 3267 IIIB/IV DC D 75 mg
N¼ 1218 C 75 mg
DCb D 75 mg
Cb AUC
Taxobel 3039 IV DC D 75 mg
N¼ 233 C 100 m
TAX 30110 IV DC D 60 mg
N¼ 311 C 80 mg
Georgoulias et al.11 Inoperable, IIIb/IV DC D 100 m
N¼ 413 G 1000 m
Pujol et al.12 IV DG D 85 mg
N¼ 311 G 1000 m
WJTOG 990414 Elderly, IIIb/IV D D 60 mg
N¼ 180
C, cisplatin; Cb, carboplatin; d, day; D, docetaxel; DC, docetaxel/cisplatin; D
every 3 weeks; Q4W, every 4 weeks; V, vinorelbine; VC, vinorelbine/cispla
S88recently conducted a meta-analysis to estimate more
precisely the magnitude of benefit of docetaxel-based
therapy in advanced NSCLC. The analysis included all
trials that compared docetaxel-based with vinca alkaloid-
based therapy in this setting, without restriction by
language. Doublet and single-agent therapy trials were
included, as were published papers (Table 2)7,9–12,14 and
meeting abstracts. All investigators were contacted in an
effort to obtain the most accurate and updated results of the
studies considered. Overall survival was the primary
endpoint of the analysis. Serious adverse events and
haematologic toxicity were also assessed. Sensitivity
analyses included a comparison of docetaxel and vinor-
elbine trials, doublet trials only, and analysis with deletion
of each trial one by one.
Once the data were reviewed, they were presented at the
2006 annual meeting of the American Society of Clinical
Oncology (ASCO). Overall, this meta-analysis provides the
first evidence that one third-generation agent, docetaxel, is
superior to another, vinorelbine, in the first-line treatment of
patients with advanced NSCLC. Further results will be
forthcoming soon.
SPECIAL POPULATIONS
Lung cancer is frequently diagnosed in the elderly.
Even though the majority of diagnoses are made in patients
over the age of 65 years, they comprise only 39% of patients
in clinical trials, and patients over the age of 80 years are
often excluded from trials by virtue of age alone.15
Therefore, few data are available to guide treatment
decisions for older patients, particularly those with multiple
co-morbidities or poor PS. Current clinical practice
guidelines from the ASCO recommend single-agent chemo-
therapy for elderly patients with advanced NSCLC.3 The
value of non-platinum-based, single-agent therapy has been
demonstrated in several trials conducted in patients 70 years
of age or older. The Elderly Lung Cancer Vinorelbineuthorized reproduction of this article is prohibited.
ids in First-Line Advanced Non-small Cell Lung Cancer.
n Vinca Alkaloid Regimen
/m2 d1 Q3W VC V 25 mg/m2 d1, 8, 15, 22 Q4W
/m2 d1 Q3W C 100 mg/m2 d1 Q4W
/m2 d1 Q3W
6 d1 Q3W
/m2 d1 Q3W VC V 30 mg/m2 d1, 8 Q3W
g/m2 d1 Q3W C 100 mg/m2 d1 Q3W
/m2 d1 Q3–4W VdC Vind 3 mg/m2 d1, 8, 15 Q4W
/m2 d1 Q3–4W C 80 mg/m2 d1 Q4W
g/m2 d8 Q3W VC V 30 mg/m2 d1, 8 Q3W
g/m2 d1, 8 Q3W C 80 mg/m2 d1, 8 Q3W
/m2 d8 Q3W VC V 30 mg/m2 d1, 8, 15, 22 Q4W
g/m2 d1, 8 Q3W C 100 mg/m2 d1 Q4W
/m2 d1 Q3W V V 25 mg/m2 d1, 8 Q4W
Cb, docetaxel/carboplatin; DG, docetaxel/gemcitabine; G, gemcitabine; Q3W,
tin; VdC, vindesine/cisplatin; Vind, vindesine.
 2007 International Association for the Study of Lung Cancer
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vinorelbine improved survival and QoL over best supportive
care in this population in the phase III ELVIS trial.16
Subsequent randomized trials evaluated single-agent
therapy compared with a combination of vinorelbine/
gemcitabine, with conflicting results. The Southern Italy
Cooperative Group compared vinorelbine with gemcitabine/
vinorelbine in 120 patients, and found significant improve-
ments in median survival with combination therapy (MST
29 versus 18 weeks, respectively; p< 0.01), as well as a
delay in the worsening of symptoms and QoL.17 Conversely,
the Multicenter Italian Lung Cancer in the Elderly Study,
which compared vinorelbine, gemcitabine, and the combi-
nation of the two in 698 elderly patients, found that the
combination was not superior to either single-agent regi-
men.18 Median survival times were 36 weeks, 28 weeks, and
20 weeks, respectively ( p¼NS). Although QoL did not
differ among treatment arms, a greater rate of toxicity was
seen with combination therapy. Independently of the results
of the above-mentioned studies, there is an increasing line of
clinical evidence that age alone is not a sufficient factor to
exclude patients between 70 and 75 years of age without
severe co-morbid conditions from receiving combination
chemotherapy.
Given its efficacy in NSCLC, several groups have
evaluated docetaxel in elderly patients with advanced
disease. The West Japan Thoracic Oncology Group recently
published complete results from WJTOG 9904, a phase III
trial comparing docetaxel with vinorelbine as first-line
therapy in elderly patients with advanced NSCLC.14 A total
of 182 patients with stage IIIB/IV NSCLC with PS 0–2 were
enrolled. Response rates and progression-free survival were
improved in the docetaxel arm; overall survival was longer
in the docetaxel arm, but not statistically significantly
different (Table 3). There were no differences in global QoL
between the two arms; however, docetaxel was associated
with a significant improvement in symptom scores,
particularly for measures of anorexia and fatigue. Both
treatments were generally well tolerated by elderly patients.
Notably, grade 3/4 haematological toxicity was significantly
more common with docetaxel (grade 3/4 neutropenia 83
versus 69%, respectively; p¼ 0.031), but the incidence of
febrile neutropenia did not differ between arms (13 versus
11%, respectively). That trial demonstrates that docetaxel
monotherapy is an appropriate option for elderly patients
with advanced NSCLC.Copyright © Adis Data Information BV. Una
TABLE 3. Results of WJTOG 9904: Docetaxel Versus Vinore
Docetaxel (n¼ 8
Median survival, months 14.3
Progression-free survival, months 5.5
Overall response rate, % 23
Complete response, % 0
Partial response, % 23
Stable disease, % 53
Progressive disease, % 21
Not assessable 3
 2007 International Association for the Study of Lung CancerDocetaxel-based doublets have also been evaluated in
elderly patients in clinical trials. In a preplanned subgroup
analysis of TAX 326, Belani and Fossella19 found that
patients aged 65 years and older receiving DC obtained
benefits similar to those of their younger counterparts. For
the 401 elderly patients in the study, median survival was
12.6 months with DC compared with 9.9 months with VC.
One-year survival was 52 and 41%, respectively, with 2-year
survival rates of 24 and 17%, respectively. Rates of grade
3/4 toxicity (in particular asthenia, infection, pain,
neurotoxicity, and pulmonary toxicity) were generally
greater in the elderly population than in the younger cohort
in all three treatment arms. Fewer patients receiving DC
(20%) discontinued treatment because of an adverse event
compared with those receiving VC (32%).
A weekly combination of docetaxel/cisplatin was safely
administered to fit, elderly patients in a small study in Japan,
where elderly patients are routinely excluded from trials
based on age alone.20 In that phase II trial, 33 patients aged
75 years and older with PS 0/1 received cisplatin 25 mg/m2
and docetaxel 20 mg/m2 on days 1, 8, and 15 of a 28-day
cycle. The weekly dosing strategy was chosen because of
concerns related to the toxicity of full-dose cisplatin
administered once per cycle to this population. The results
of this phase II trial are encouraging, with respect to both
response and tolerability. The majority of patients responded
to treatment (overall response rate 52%), with a median
survival time of 15.8 months. Grade 4 toxicity was not
observed, whereas grade 3 neutropenia occurred in 12% of
patients. The Japanese Clinical Oncology Group is currently
conducting a randomized phase III trial (JCOG0207)
comparing weekly single-agent docetaxel with weekly
docetaxel plus cisplatin in NSCLC patients 70 years of
age and older.21 Results are expected in 2007, and will
provide important information about the risks and benefits of
doublet therapy in elderly patients with advanced NSCLC.
Performance status is a well-known independent
prognostic factor. Median survival and response rates are
both lower for PS 2 patients than for those with PS 0 or
PS 1.22 There is a continued perception that the risk of
toxicity is greater for PS 2 patients, and the current ASCO
clinical practice guidelines recommend single-agent
chemotherapy for both PS 2 and elderly patients.3
Guidelines from the European Expert Panel, however,
recognize that there is a need to distinguish elderly
patients from poor PS patients.22 At the current time,uthorized reproduction of this article is prohibited.
lbine in Elderly Patients.14
8) Vinorelbine (n¼ 91) P value
9.9 0.14
3.1 < 0.001
10 0.019
0
10
50
37
3
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Scagliotti Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007docetaxel-based therapy has been evaluated in the combined
population of elderly/poor PS patients.
Weekly docetaxel retains efficacy but has improved
tolerability over standard therapy in elderly/poor PS
patients with advanced NSCLC.23 Docetaxel 30 mg/m2
given on days 1, 8, and 15 every 4 weeks was compared
with docetaxel 75 mg/m2 every 3 weeks as first-line
therapy for patients 70 years of age or older (with PS 0–2)
or patients of any age with PS 2. The median age was 75
years; approximately half of the patients were PS 2. There
were no differences between groups with regard to the
overall response rate or median survival time among the
69 evaluable patients. The incidence of grade 3/4
neutropenia was, however, significantly reduced with
weekly therapy (no cases with weekly therapy versus 30%
with 3-weekly docetaxel; p¼ 0.0001).
Although clinical trials generally demonstrate the
tolerability of docetaxel in elderly and PS 2 patients, it
should be noted that some patients experience side effects,
such as facial swelling, leg oedema, and the new
development or worsening of pleural effusion, which may
be more common with dosing every 3 weeks. Because these
events may be cumulative in nature, they can become a
limiting factor for some patients in our practices. Another
relevant issue, especially for women, is the potential for
complete alopecia. Clinicians should discuss the risks and
benefits of therapy with each patient.
In conclusion, docetaxel-based doublets are among the
most active treatments in advanced NSCLC, with survival
and QoL benefits demonstrated for the docetaxel/cisplatin
combination in one of the largest phase III trials conducted
to date.7 For patients who are not suitable candidates for
platinum-based therapy, a combination of docetaxel/
gemcitabine is a viable treatment option, with efficacy
similar to that of vinorelbine/cisplatin but improved
tolerability. In special populations such as the elderly or
patients with PS 2, single-agent docetaxel is an option.
Weekly dosing may be appropriate for patients with poor PS.
Results from ongoing trials will further define the role of
docetaxel-based doublets in poor PS and elderly patients
with advanced NSCLC.
REFERENCES
1. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of rando-
mized clinical trials comparing cisplatin to carboplatin in
patients with advanced non-small-cell lung cancer. J Clin
Oncol 2004;22:3852–3859.
2. Ardizzoni A, Tiseo M, Boni L, et al. CISCA (cisplatin vs.
carboplatin) meta-analysis: an individual patient data meta-
analysis comparing cisplatin versus carboplatin-based che-
motherapy in first-line treatment of advanced non-small cell
lung cancer (NSCLC). ASCO Annual Meeting Proceedings
Part I. Vol 24, No. 18S (June 20 Supplement). J Clin Oncol
2006; 7011. Updated based on presentation.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of
ClinicalOncology treatment ofunresectable non-small-cell lung
cancer guideline: update 2003. J Clin Oncol 2004;22:330–353.
4. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial
of paclitaxel plus carboplatin versus vinorelbine plus cisplatin inCopyright © Adis Data Information BV. Una
S90the treatment of patients with advanced non-small-cell lung
cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001;
19:3210–3218.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four
chemotherapy regimens for advanced non-small-cell lung
cancer. N Engl J Med 2002;346:92–98.
6. Scagliotti GV, DeMarinis F, Rinaldi M, et al. Phase III
randomized trial comparing three platinum-based doublets
in advanced non-small-cell lung cancer. J Clin Oncol 2002;
20:4285–4291.
7. Fossella F, Pereira JR, von Pawel J, et al. Randomized,
multinational, phase III study of docetaxel plus platinum
combinations versus vinorelbine plus cisplatin for advanced
non-small-cell lung cancer: the TAX 326 study group. J Clin
Oncol 2003;21:3016–3024.
8. Belani CP, Pereira JR, von Pawel J, et al., TAX 326 study
group. Effect of chemotherapy for advanced non-small cell
lung cancer on patients’ quality of life. A randomized con-
trolled trial. Lung Cancer 2006;53:231–239.
9. Douillard JY, Gervais R, Dabouis G, et al. Sequential two-line
strategy for stage IV non-small-cell lung cancer: docetaxel–
cisplatin versus vinorelbine–cisplatin followed by cross-over
to single-agent docetaxel or vinorelbine at progression: final
results of a randomised phase II study. Ann Oncol 2005;16:
81–89.
10. Kubota K, Watanabe K, Kunitoh H, et al., Japanese Taxotere
Lung Cancer Study Group. Phase III randomized trial of
docetaxel plus cisplatin versus vindesine plus cisplatin in
patients with stage IV non-small-cell lung cancer: the Japanese
Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:
254–261.
11. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine
plus cisplatin versus docetaxel plus gemcitabine in advanced
non-small-cell lung cancer: a phase III randomized trial.
J Clin Oncol 2005; 23:2937-2945. E-pub 22 February 2005.
12. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel
versus cisplatin-vinorelbine in advanced or metastatic non-
small-cell lung cancer: a phase III study addressing the case for
cisplatin. Ann Oncol 2005;16:602–610.
13. Douillard JY, Fossela F, Georgoulias V, et al. Comparison of
docetaxel and vinca alkaloid, alone or in combination with other
chemotherapy agents, in the first-line treatment of advanced
non-small cell lung cancer (NSCLC): a meta-analysis
ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S
(June 20 Supplement). J Clin Oncol 2006; 7034.
14. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of
docetaxel compared with vinorelbine in elderly patients with
advanced non-small-cell lung cancer: results of the West Japan
Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol
2006;24:3657–3663.
15. Gridelli C, Shepherd FA. Chemotherapy for elderly patients
with non-small cell lung cancer: a review of the evidence.
Chest 2005;128:947–957.
16. Gridelli C. The ELVIS trial: a phase III study of single-agent
vinorelbine as first-line treatment in elderly patients with
advanced non-small cell lung cancer. Elderly Lung Cancer
Vinorelbine Italian Study. Oncologist 2001;6 (Suppl. 1):4–7.
17. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
vinorelbine versus vinorelbine alone in elderly patients with
advanced non-small-cell lung cancer. J Clin Oncol 2000;18:
2529–2536.
18. Gridelli C, Perrone F, Gallo C, et al. MILES Investiga-
tors. Chemotherapy for elderly patients with advanceduthorized reproduction of this article is prohibited.
 2007 International Association for the Study of Lung Cancer
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Chemotherapy for Advanced NSCLCnon-small-cell lung cancer: the Multicenter Italian Lung Can-
cer in the Elderly Study (MILES) phase III randomized trial.
J Natl Cancer Inst 2003;95:362–372.
19. Belani CP, Fossella F. Elderly subgroup analysis of a rando-
mized phase III study of docetaxel plus platinum combinations
versus vinorelbine plus cisplatin for first-line treatment of
advanced nonsmall cell lung carcinoma (TAX 326). Cancer
2005;104:2766–2774.
20. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin
and docetaxel administered as three consecutive weekly infu-
sions for advanced non-small-cell lung cancer in elderly
patients. Ann Oncol 2004;15:45–50.Copyright © Adis Data Information BV. Una
 2007 International Association for the Study of Lung Cancer21. Clinicaltrials.gov website. Elderly NSCLC/D Vs DP
(JCOG0207). Available at: http://www.clinicaltrials.gov/
show/NCT00190476. Accessed: 1 October 2006.
22. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of
advanced non-small-cell lung cancer patients with ECOG
performance status 2: results of an European Experts Panel.
Ann Oncol 2004;15:419–426.
23. Lilenbaum R, Rubin M, Samuel J, et al. A phase II randomized
trial of docetaxel weekly or every 3 weeks in elderly and/or
poor performance status (PS) patients (pts) with advanced non-
small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol
2004; 22. Abstract 7057. Updated based on presentation.uthorized reproduction of this article is prohibited.
S91
